Aptamer Group PLC Posting of Annual Report and Notice of AGM (9030T)
20 Novembre 2023 - 8:00AM
UK Regulatory
TIDMAPTA
RNS Number : 9030T
Aptamer Group PLC
20 November 2023
20 November 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Posting of Annual Report and Accounts and Notice of Annual
General Meeting
Aptamer Group plc (AIM: APTA ), the developer of novel Optimer
(R) binders to enable innovation in the life sciences industry,
today announces that the Annual Report and Accounts for the year
ended 30 June 2023 and Notice of its 2023 Annual General Meeting
(AGM) were posted to shareholders today. These documents are
available on the company's website at
https://aptamergroup.com/.
Aptamer will host its AGM at 10:00 GMT on 15 December 2023 at
Windmill House, Innovation Way, York, YO10 5BR. The AGM will be
held in person only and there will be no new information presented
at the meeting.
The results of voting on all resolutions at the AGM will be
announced via a Regulatory News Service and the full results of the
voting will be published on the Company's website, as soon as
practicable after the conclusion of the AGM.
- ENDS -
For further information, please contact:
Aptamer Group plc
Steve Hull +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam Dawes +44 (0) 20 3368 3550
T urner Pope I nvestments (TPI) Limited
- B roker
J ames Pope / Andrew Thacker +44 (0) 20 36 57 0 050
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its
proprietary Optimer (R) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers through the use of its
proprietary Optimer(R) platform.
Optimer(R) binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global affinity ligand
market is currently worth over $170 billion. Optimer(R) binders are
engineered to address many of the issues found with alternative
affinity molecules, such as antibodies, and offer new, innovative
solutions to bioprocessing, diagnostic and pharmaceutical
scientists.
Aptamer has successfully delivered projects for global pharma
companies, diagnostic development companies and research institutes
covering a range of targets and applications with the objective of
establishing royalty-bearing licenses. Through the unique
Optimer(R) technology and processes, scientists and collaborators
can make faster, more informed decisions that support discovery and
development across the Life Sciences.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAEASFNFLKDFFA
(END) Dow Jones Newswires
November 20, 2023 02:00 ET (07:00 GMT)
Grafico Azioni Aptamer (LSE:APTA)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Aptamer (LSE:APTA)
Storico
Da Set 2023 a Set 2024